Skip to content
Screener

Leonardo DRS, Inc. DRS IMS — Total company-funded independent research and development

Other segment segments

ASC
$24M+4.3%

Similar metrics at other companies

CorMedix logo
CRMDOther research and development — Total research and development
$4.87M+133%
Disc Medicine logo
IRONInternal Research And Development — Research And Development Expense
$11.31M+67.6%
Keysight Technologies logo
KEYSTotal segments — Research and Development Expense
$303M+27.3%
Beam Therapeutics logo
BEAMExternal Research And Development Expenses — Research And Development Expense
$30.08M-12.6%
Solid Biosciences Inc. logo
SLDBInternal Research And Development Expense — Research And Development Expense
$9.06M+33.9%
Fulgent Genetics, Inc. logo
FLGTTherapeutic Development — Research And Development Expense
$4.18M+4.7%

Other financials

Income statement

See full
Revenue$846.0M+5.9%
Gross profit$212.0M+17.1%
Operating income$77.0M+30.5%
Net income$62.0M+24.0%
EPS (diluted)$0.23+21.1%

Balance sheet

See full
Cash & equivalents$328.0M-13.7%
Total debt$170.0M-53.7%
Total equity$2.8B+7.7%
Total assets$4.2B+2.8%

Cash flow

See full
Operating cash flow-$66.0M+52.2%
CapEx$30.0M-6.3%
Free cash flow-$96.0M+43.5%

Valuation

See full
Market cap$11.91B+8.3%
Enterprise value$11.75B+6.1%
P/E41.1×-2.9×
P/S3.2×0.0×

Profitability

See full
Gross margin24.4%+1.5pp
Operating margin9.9%+0.7pp
Net margin7.8%+0.9pp
FCF margin8.1%—

Returns & leverage

See full
Return on equity10.9%+1.4pp
Debt / equity0.1×-0.1×
Current ratio1.9×-0.2×

Where this comes from

Reported directly by Leonardo DRS, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The source filing: Leonardo DRS, Inc.’s 10-Q, filed May 5, 2026.

Filed
May 5, 2026, 4:36 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001833756-26-000025
(Dollars in millions)Three Months Ended March 31, 20262025
Total general and administrative$99$89
Company-funded independent research and development
ASC$24$23
IMS75
Corporate & Eliminations——
Total company-funded independent research and development$31$28
Amortization of acquired intangible assets
ASC$5$5

ITEM 1. FINANCIAL STATEMENTS (UNAUDITED)

FAQ

What is Leonardo DRS, Inc.'s IMS — total company-funded independent research and development?
Leonardo DRS, Inc. (DRS) reported IMS — total company-funded independent research and development of $7M in Q1 2026.
How has Leonardo DRS, Inc.'s IMS — total company-funded independent research and development changed year-over-year?
Leonardo DRS, Inc.'s IMS — total company-funded independent research and development increased by 40.0% year-over-year, from $5M to $7M.
What is the long-term trend for Leonardo DRS, Inc.'s IMS — total company-funded independent research and development?
Over 3 years (2022 to 2025), Leonardo DRS, Inc.'s IMS — total company-funded independent research and development has grown at a 21.3% compound annual growth rate (CAGR), from $14M to $25M.
What does IMS — total company-funded independent research and development mean?
Reflects the internal investment made by the segment into new technologies and product innovation without direct customer reimbursement. This is a key indicator of the segment's commitment to future product pipelines and competitive differentiation.

Ask your AI about Leonardo DRS, Inc.'s ims — total company-funded independent research and development.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude